Esperion Completes Corstasis Acquisition, Adds FDA-Approved Enbumyst to Cardiovascular Portfolio

summarizeSummary

Esperion Therapeutics completed the acquisition of Corstasis Therapeutics for $75 million upfront, adding the FDA-approved drug Enbumyst to its cardiovascular portfolio, and secured $25 million in new debt and $50 million from a royalty sale to finance the deal.

check_boxKey Events

• Acquisition of Corstasis Therapeutics Completed

  Esperion completed the acquisition of Corstasis Therapeutics Inc. for an upfront cash consideration of $75 million, with potential milestone payments up to an aggregate of $180 million and additional royalty-derived payments.

• Cardiovascular Portfolio Expanded with Enbumyst

  The acquisition integrates Enbumyst (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic, into Esperion's portfolio, targeting edema associated with congestive heart failure, hepatic, and renal disease.

• New Term Loan Facility Secured

  Esperion secured an additional $25 million in term loans through an amendment to its existing credit agreement, which will be used to partially finance the Corstasis acquisition.

• Royalty Monetization Agreement Executed

  The company sold a portion of its future royalties and milestones on Bempedoic Acid and other Licensed Products in the Otsuka Territory for $50 million in cash. The purchaser will receive 100% of these receivables until an aggregate of $100 million is received, after which all rights revert to Esperion.

auto_awesomeAnalysis

This 8-K filing details the completion of Esperion's strategic acquisition of Corstasis Therapeutics, a move previously confirmed in the company's recent 10-K. The acquisition, with an upfront cash payment of $75 million and potential future milestones up to $180 million, significantly expands Esperion's cardiovascular franchise by adding Enbumyst, an FDA-approved nasal spray loop diuretic. This product is expected to drive revenue growth and leverage Esperion's existing commercial infrastructure. To partially finance this acquisition, Esperion secured an additional $25 million in term loans and monetized $50 million in future royalties and milestones. While the royalty sale provides non-dilutive capital, it represents a trade-off of future revenue streams for immediate cash. Overall, this is a highly important event, marking a substantial strategic expansion for Esperion with both immediate financial implications and long-term growth potential.